PURPOSE: Urine proteomics is emerging as a powerful tool for biomarker discovery. The purpose of this study is the development of a well-characterized "real life" sample that can be used as reference standard in urine clinical proteomics studies. EXPERIMENTAL DESIGN: We report on the generation of male and female urine samples that are extensively characterized by different platforms and methods (CE-MS, LC-MS, LC-MS/MS, 1-D gel analysis in combination with nano-LC MS/MS (using LTQ-FT ultra), and 2-DE-MS) for their proteome and peptidome. In several cases analysis involved a definition of the actual biochemical entities, i.e. proteins/peptides associated with molecular mass and detected PTMs and the relative abundance of these compounds. RESULTS: The combination of different technologies allowed coverage of a wide mass range revealing the advantages and complementarities of the different technologies. Application of these samples in "inter-laboratory" and "inter-platform" data comparison is also demonstrated. CONCLUSIONS AND CLINICAL RELEVANCE: These well-characterized urine samples are freely available upon request to enable data comparison especially in the context of biomarker discovery and validation studies. It is also expected that they will provide the basis for the comprehensive characterization of the urinary proteome.
PURPOSE: Urine proteomics is emerging as a powerful tool for biomarker discovery. The purpose of this study is the development of a well-characterized "real life" sample that can be used as reference standard in urine clinical proteomics studies. EXPERIMENTAL DESIGN: We report on the generation of male and female urine samples that are extensively characterized by different platforms and methods (CE-MS, LC-MS, LC-MS/MS, 1-D gel analysis in combination with nano-LC MS/MS (using LTQ-FT ultra), and 2-DE-MS) for their proteome and peptidome. In several cases analysis involved a definition of the actual biochemical entities, i.e. proteins/peptides associated with molecular mass and detected PTMs and the relative abundance of these compounds. RESULTS: The combination of different technologies allowed coverage of a wide mass range revealing the advantages and complementarities of the different technologies. Application of these samples in "inter-laboratory" and "inter-platform" data comparison is also demonstrated. CONCLUSIONS AND CLINICAL RELEVANCE: These well-characterized urine samples are freely available upon request to enable data comparison especially in the context of biomarker discovery and validation studies. It is also expected that they will provide the basis for the comprehensive characterization of the urinary proteome.
Authors: M T Davis; C S Spahr; M D McGinley; J H Robinson; E J Bures; J Beierle; J Mort; W Yu; R Luethy; S D Patterson Journal: Proteomics Date: 2001-01 Impact factor: 3.984
Authors: Stefan Schaub; John Wilkins; Tracey Weiler; Kevin Sangster; David Rush; Peter Nickerson Journal: Kidney Int Date: 2004-01 Impact factor: 10.612
Authors: Marion Haubitz; David M Good; Alexander Woywodt; Hermann Haller; Harald Rupprecht; Dan Theodorescu; Mohammed Dakna; Joshua J Coon; Harald Mischak Journal: Mol Cell Proteomics Date: 2009-06-28 Impact factor: 5.911
Authors: Lukas U Zimmerli; Eric Schiffer; Petra Zürbig; David M Good; Markus Kellmann; Laetitia Mouls; Andrew R Pitt; Joshua J Coon; Roland E Schmieder; Karlheinz H Peter; Harald Mischak; Walter Kolch; Christian Delles; Anna F Dominiczak Journal: Mol Cell Proteomics Date: 2007-10-19 Impact factor: 5.911
Authors: Janet K Snell-Bergeon; David M Maahs; Lorraine G Ogden; Gregory L Kinney; John E Hokanson; Eric Schiffer; Marian Rewers; Harald Mischak Journal: Diabetes Technol Ther Date: 2009-01 Impact factor: 6.118
Authors: Dan Theodorescu; Stefan Wittke; Mark M Ross; Michael Walden; Mark Conaway; Ingo Just; Harald Mischak; Henry F Frierson Journal: Lancet Oncol Date: 2006-03 Impact factor: 41.316
Authors: Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt Journal: Expert Opin Med Diagn Date: 2013-11
Authors: Steven L Wood; Margaret A Knowles; Douglas Thompson; Peter J Selby; Rosamonde E Banks Journal: Nat Rev Urol Date: 2013-02-26 Impact factor: 14.432
Authors: Constantin von zur Muhlen; Eric Schiffer; Christine Sackmann; Petra Zürbig; Irene Neudorfer; Andreas Zirlik; Nay Htun; Alexander Iphöfer; Lothar Jänsch; Harald Mischak; Christoph Bode; Yung C Chen; Karlheinz Peter Journal: Mol Cell Proteomics Date: 2012-02-27 Impact factor: 5.911
Authors: A Aggarwal; R Gupta; V S Negi; L Rajasekhar; R Misra; P Singh; V Chaturvedi; S Sinha Journal: Clin Exp Immunol Date: 2017-02-23 Impact factor: 4.330